Rational Advisors LLC Bluebird Bio, Inc. Transaction History

Rational Advisors LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 05, 2021	SELL	$27.5 - $37.92 $4,070 - $5,612	-148 Closed	0 $0
Q3 2020 Nov 12, 2020	SELL	$34.44 - $43.75 $792 - $1,006	-23 Reduced 13.45%	148 $8,000
Q2 2020 Aug 10, 2020	BUY	$27.12 - $45.97 $4,637 - $7,860	171 New	171 $10,000
Q1 2020 May 12, 2020	SELL	$26.16 - $63.5 $18,521 - $44,958	-708 Closed	0 $0
Q4 2019 Feb 06, 2020	BUY	$46.96 - $61.67 $14,839 - $19,487	316 Added 80.61%	708 $62,000
Q3 2019 Nov 06, 2019	BUY	$59.47 - $93.1 $19,625 - $30,722	330 Added 532.26%	392 $36,000
Q2 2019 Aug 08, 2019	BUY	$75.84 - $105.21 $3,261 - $4,524	43 Added 226.32%	62 $8,000
Q1 2019 May 08, 2019	SELL	$64.44 - $104.11 $14,499 - $23,424	-225 Reduced 92.21%	19 $3,000
Q4 2018 Feb 07, 2019	BUY	$59.1 - $93.26 $10,578 - $16,693	179 Added 275.38%	244 $24,000
Q3 2018 Nov 08, 2018	BUY	$88.86 - $117.49 $4,976 - $6,579	56 Added 622.22%	65 $9,000
Q2 2018 Aug 07, 2018	SELL	$99.64 - $127.59 $7,373 - $9,441	-74 Reduced 89.16%	9 $1,000
Q1 2018 May 18, 2018	BUY	$105.8 - $150.94 $8,781 - $12,528	83 New	83 $14,000

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $27M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Rational Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Rational Advisors LLC with notifications on news.